USSN: 10/552,426 Page 2 of 24

## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

#### LISTING OF CLAIMS:

- 1-8 (cancelled)
- 9. (currently amended) The compound according to claim 8, of Formula IV.

$$(R^1)_{1.4}$$
 $(R^5)_{1.2}$ 
 $(R^4)_{0.3}$ 

or a pharmaceutically acceptable salt thereof, wherein

X is selected from -H,  $-OR^6$ ,  $-S(O)_{0.2}R^6$ ,  $-N(R^6)R^7$ ,  $-O-N(R^6)R^7$ ,  $-N(R^6)OR^6$ ,  $-N(R^6)N(R^6)R^7$ , absent, oxo, thiono, and imino, with the proviso that when X is oxo, thiono, or imino, there is only one  $R^1$ ;

R<sup>1</sup> and R<sup>2</sup>, at each occurance, are each independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -S(O)<sub>0.2</sub>R<sup>7</sup>, -SO<sub>2</sub>N(R<sup>6</sup>)R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, absent, and optionally substituted lower heterocyclylalkyl;

# optionally two of R<sup>2</sup> together are oxo;

optionally, at least one pair of substituents, selected from two of R<sup>1</sup>, two of R<sup>2</sup>, and one each of R<sup>1</sup> and R<sup>2</sup>, together with the corresponding carbon or carbons to which they are attached, form a first ring comprising between three and seven annular atoms, said first ring optionally substituted with between zero and four additional of R<sup>1</sup>, each independently selected as defined above and optionally, when paired, together with the

corresponding atom or atoms of the first ring to which they are attached, form a second ring comprising between three and seven annular atoms, said second ring optionally substituted with between zero and three of R<sup>1</sup>;

R<sup>3</sup> is selected from -H, optionally substituted lower alkyl, optionally substituted lower arylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted alkoxy;

optionally R<sup>3</sup> and one of R<sup>2</sup>, together with the atoms to which each is attached, form a third ring comprising between three and seven annular atoms, said third ring optionally substituted with between zero and four additional of R<sup>1</sup>, each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the third ring to which they are attached, form a fourth ring comprising between three and seven annular atoms, said fourth ring optionally substituted with between zero and three of R<sup>1</sup>;

optionally R<sup>3</sup> and one of R<sup>1</sup>, together with the atoms to which they are attached and the carbon to which R<sup>2</sup> is attached, form a fifth ring comprising between three and seven annular atoms atoms, said fifth ring optionally substituted with between zero and four additional of R<sup>1</sup>, each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the fifth ring to which they are attached, form a sixth ring comprising between three and seven annular atoms, said sixth ring optionally substituted with between zero and three of R<sup>1</sup>;

### m is zero to four;

each of  $R^4$  is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>N(R<sup>6</sup>)R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

each Y is independently either  $=C(R^5)$ - or =N-, provided that there are no more than three of =N- in the aromatic ring bearing Y;

USSN: 10/552,426 Page 4 of 24

each Z is independently either =C(R4)- or =N-;

n is zero to five;

each  $R^5$  is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

## $R^6$ is -H or $R^7$ :

R<sup>7</sup> is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

R<sup>6</sup> and R<sup>7</sup>, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P.

- 10. (original) The compound according to claim 9, wherein X is selected from -OR<sup>6</sup>, -SR<sup>6</sup>, and -N(R<sup>6</sup>)R<sup>7</sup>.
- 11. (original) The compound according to claim 10, wherein two of R<sup>1</sup>, together with the carbon or carbons to which they are attached, form said second ring.
- 12. (original) The compound according to claim 11, wherein said second ring is a six-membered aryl, fused with said first ring, said second ring optionally substituted with between zero and three of R<sup>1</sup>.
- 13. (original) The compound according to claim 12, of formula V.

USSN: 10/552,426 Page 5 of 24

$$(R^{1})_{0-3}$$
 $(R^{4})_{0-3}$ 
 $(R^{5})_{0}$ 

- 14. (original) The compound according to claim 13, wherein X is -OR<sup>6</sup>.
- 15. (original) The compound according to claim 14, wherein R<sup>3</sup> is -H.
- 16. (original) The compound according to claim 15, wherein X is -OH.
- 17. (original) The compound according to claim 16, of formula VI.

$$(R^1)_{0.3}$$
 $(R^5)_{n}$ 
 $(R^4)_{0.3}$ 

- 18. (original) The compound according to claim 17, wherein R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> are -H.
- 19-29. (cancelled)
- 30. (currently amended) The A compound according to elaim-1, selected from Table 3. 3:

Table 3

#	Name	Structure
1	N-cyclohexyl-2-pyridin-4-ylquinazolin-4- amine	HN——N

USSN: 10/552,426 Page 6 of 24

Table 3

	1 able	
#	Name	Structure
2	2 py <del>ridin 4 yl N (2 pyrrolidin 1</del> <del>ylethyl)quinazolin 4 amine</del>	HN N
3	N-cyclopentyl-2-pyridin-4-ylquinazolin-4- amine	HN Z Z
4	N-(cyclohexylmethyl)-2-pyridin-4- ylquinazolin-4-amine	HN Z Z
\$	<del>2 [(2 pyridin 4 ylquinazolin 4</del> <del>yl)amino]ethanol</del>	HN N N N N N N N N N N N N N N N N N N
6	3-[(2-pyridin 1-ylquinazolin 1-yl)amino]propan-1-ol	
7	N-[(4-fluorophenyl)methyl]-2-pyridin-4- ylquinazolin-4-amine	

USSN: 10/552,426 Page 7 of 24

Table 3

	Table	
#	Name	Structure
8	N,N-dimethyl N' (2 pyridin 4- ylquinazolin 4-yl)ethane-1,2 diamine	HN N
9	N-(2,3-dihydro-1H-inden-1-yl)-2-pyridin- 4-ylquinazolin-4-amine	
10	N-(2 morpholin 4-ylethyl) 2 pyridin 4- ylquinazolin-4 amine	HN N
11	4-[4-(2-pyridin 4-ylquinazolin-4- yl)piperazin 1-yl]phenol	HO—N—N—N
12	2-pyridin-4-yl-N-[(2R)-1,2,3,4- tetrahydronaphthalen-2-yl]quinazolin-4- amine	HN
13	4 piperazin 1 yl 2 pyridin 4 ylquinazoline	HN N—N

USSN: 10/552,426 Page 8 of 24

Table 3

#	Name	Structure
14	1,1 dimethylethyl 4-(2-pyridin-4- ylquinazolin-4-yl)piperazine 1 carboxylate	
15	2-pyridin-4-yl-N-[(2S)-1,2,3,4- tetrahydronaphthalen-2-yl]quinazolin-4- amine	HN N
16	4-[(1S)-2,3-dihydro-1H-inden-1- ylmethyl]-2-pyridin-4-ylquinazoline	
17	(1R,2S) 1 [(2 pyridin 4 ylquinazolin 4 yl)amino] 2,3 dihydro 1H inden 2 ol	HO Z Z
18	(1S,2R)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

USSN: 10/552,426 Page 9 of 24

Table 3

	Table	
#	Name	Structure
19	1,1-dimethylethyl 4-[(2-pyridin-4- ylquinazolin-4-yl)amino]piperidine-1- carboxylate	HN—N—O+
<del>20</del>	2 pyridin 4 yl-N {[2,4,6- tris(methyloxy)phenyl]methyl}quinazolin 4 amine	N=N N=N
21.	N-piperidin 4-yl-2-pyridin 4-ylquinazolin- 4-amine	HN NH
22	N-{(18,28)-2- [(phenylmethyl)oxy]cyclopentyl}-2- pyridin 4-ylquinazolin 4-amina	HN
23	N-phenyl-N' (2 pyridin 4 ylquinazelin 4 yl)benzene 1,4 diamine	

USSN: 10/552,426 Page 10 of 24

Table 3

#	Name	Structure
24	3-[(2-pyridin-4-ylquinazolin-4- yl)amino]naphthalen-2-ol	HO HO Z Z
25	N-{4-[(1-methylethyl)oxy]phenyl}-2- pyridin-4-ylquinazolin-4-amine	HN N N
<del>26</del>	(1S,2R) 1-[(2-phonylquinazolin 4- yl)amino] 2,3-dihydro 1H inden-2-ol	HN—N N= NOH
27	(1R,2S)-1-[(2 phenylquinazolin-4-yl)amino] 2,3-dihydro 1H indon-2-ol	HN—N N=OH
28	(1R,2R) 2 [(2 phenylquinazolin 4 yl)amino]cyclopentanol	N OH

USSN: 10/552,426 Page 11 of 24

Table 3

	Table	,
#	Name	Structure
29.	(1R,2R) 2 <del>[(2 phenylquinazolin 4</del> <del>yl)amino]cyclohexanol</del>	N OH OH
30	(1S,2R,3R,5R)-3-(hydroxymethyl) 5-[(2-phenylquinazolin-4-yl)amino]cyclopentane 1,2-diol	HOOH
31	(1S,2R)-1-[(6-chloro-2-pyridin-4- ylquinazolin-4-yl)amino]-2,3-dihydro-1H- inden-2-ol	HO: NH
32	N (2 piperazin 1 ylothyl) 2 pyridin 4- ylquinazolin 4 amine	N NH NH
33	(IS,2R)-1-[(2-pyridin-3-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-

USSN: 10/552,426 Page 12 of 24

Table 3

	Table 3		
#	Name	Structure	
34	(1R,2S) 1 [(2 pyridin 3 ylquinazolin 4 yl)amino] 2,3 dihydro 1H inden 2 ol	HN N	
35	(1R,2R)-2-[(2-pyridin-3-ylquinazolin-4- yl)amine]eyelopentanol	NH OH	
36	(1R,2R) 2 [(2-pyridin-3-ylquinazolin-4- yl)amino]cyclohexanol	N NH OH	
37	(1S,2R) 1 [(2 pyridin 2 ylquinazolin 4- yl)amino] 2,3 dihydro 1H inden 2-ol	HN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	
38	(1R,2S) 1-[(2 pyridin 2 ylquinazolin-4- yl)amino] 2,3 dihydro 1H-inden 2 ol	HN—N N= OH N	

USSN: 10/552,426 Page 13 of 24

Table 3

	1 a Die 3		
#	Name	Structure	
<del>39</del>	(28) 3 [(2-pyridin 4 ylquinazolin 4 yl)amino]propane 1,2 diol	HO N NH OH	
40	[(2S) 1-(2-pyridin 4-ylquinazolin 4-yl)- 2,3-dihydro 1H-indol-2-yl]methanol	HO IIII N	
41	(2R) 2-[(2 pyridin 4 ylquinazolin 4 yl)amino]propan-l-ol	HO NH	
42	(28) 1-[(2-pyridin-4-ylquinazolin-4- yl)amino]propan-2-ol	N—NH OH	
43	(1S,2R) 1 {[2-(2-ethylpyridin 4-yl)quinazolin 4-yl]amino}-2,3-dihydro- 1H-inden-2-ol	HO N N	

USSN: 10/552,426 Page 14 of 24

Table 3

#	Name	. Structure
44	(1R,2S) 1 {[2 (2 othylpyridin 4 yl)quinazolin-4 yl]amino} 2,3 dihydro lH-inden 2 ol	NH HO Z Z
45	(1S,2R)-1-[(6-bromo-2-pyridin-4- ylquinazolin-4-yl)amino]-2,3-dihydro-1H- inden-2-ol	HO N NH
46	(1S,2R)-1-{[6,7-bis(methyloxy)-2-pyridin-4-ylquinazolin-4-yl]amino}-2,3-dihydro-1H-inden-2-ol	HO: N NH
47	1 (2 pyridin 4 ylquinazolin 4 yl)piperidin 3 ol	N—N OH
48	(1S,2R)-1-{[2-pyridin-4-yl-7- (trifluoromethyl)quinazolin-4-yl]amino}- 2,3-dihydro-1H-inden-2-ol	HO: N NH

USSN: 10/552,426 Page 15 of 24

Table 3

	1 able	
#	Name	Structure
49	(1S,2R)-1-({2-[6-(methyloxy)pyridin-3-yl]quinazolin-4-yl}amino)-2,3-dihydro-1H-inden-2-ol	HN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
<del>50</del>	N [(38)-piperidin 3-yl] 2-pyridin-4- ylquinazolin-4 amine	N NH NH
51	(1S,2R)-1-[(7-methyl-2-pyridin-4- ylquinazolin-4-yl)amino]-2,3-dihydro-1H- inden-2-ol	HN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
<del>52</del>	(1S,2R)-1-({2 {2,4-bis(methyloxy)pyrimidin-5-yl}quinazolin-4-yl}amino) 2,3 dihydro 1H-inden-2-ol	I OH ON ON
53	(2R)-3-methyl 2 [(2-pyridin 4- ylquinazolin 4-yl)amino]butan-1-ol	OH N NH

USSN: 10/552,426 Page 16 of 24

Table 3

	1 able	
#	Name	Structure
54	(2S)-3-methyl-2-[(2-pyridin-4- ylquinazolin-4-yl)amino]butan-1-ol	N—OH N—NH
55	(2S)-2-phenyl-2-[(2-pyridin-4- ylquinazolin-4-yl)amino]ethanol	N—NH OH
56	(2R)-2-phenyl-2-[(2-pyridin-4- ylquinazolin-4-yl)amino]ethanol	OH NH
57	(1S,2R)-1-[(2-pyridin-4-ylpyrimidin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
<del>58</del>	(1S,2R) 1-[(2 pyrazin 2 ylquinazolin 4-yl)amino] 2,3 dihydro 1H-inden 2-ol	HN-NN N
<del>59</del>	(18,2R) 1-{[2-(4-aminopyridin 3- yl)quinazolin 4-yl]amino} 2,3-dihydro 1H-indon-2-ol	HN—N NH <sub>2</sub>

USSN: 10/552,426 Page 17 of 24

Table 3

#	Name	Structure
60	(2R)-3-phenyl-2 ((2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol	HO NH
61	(2S)-3-phenyl-2-[(2-pyridin-4- ylquinazolin-4-yl)amino]propan-1-ol	HO ZH Z
62	2-[(phenylmethyl)(2-pyridin-4- ylquinazolin-4-yl)amino]ethanol	N OH
63	(1S,2R)-1-{[2-(2-aminopyrimidin-4- yl)quinazolin-4-yl]amino}-2,3-dihydro- 1H-inden-2-ol	HN—N N=N H <sub>2</sub> N
64	5 (4 {[(18,2R) 2 hydroxy 2,3-dihydro- 1H-indon-1 yl]amino}quinazolin 2- yl)pyridin 2 ol	HN N N OH

USSN: 10/552,426 Page 18 of 24

Table 3

1 able 3		
#	Name	Structure
65	(1S,2R) 1 ({2 {2 (methylthie)pyrimidin- 4 yl]quinazolin 4 yl}amino) 2,3 dihydro- 1H-inden 2 ol	HN N N N N N N N N N N N N N N N N N N
66	2-{4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperazin-1-yl}ethanol	
67	N-piperidin-1-yl-2-pyridin-4- ylquinazolin-4-amine	

- 31. (currently amended) A pharmaceutical composition comprising the compound according to any one of claims 1 31 9 and a pharmaceutically acceptable carrier.
  - 32. (currently amended) A metabolite of the compound or the pharmaceutical composition according to any one of claims 1-31 9.

33-38. (cancelled)